{"version":"1.0","provider_name":"Market Newsdesk","provider_url":"https:\/\/www.marketnewsdesk.com","author_name":"Newsdesk","author_url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/","title":"VIBATIV\u00ae RECEIVES MARKETING APPROVAL IN CHINA - Market Newsdesk","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"W1UsSze2Ir\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/vibativ-receives-marketing-approval-in-china\/\">VIBATIV\u00ae RECEIVES MARKETING APPROVAL IN CHINA<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.marketnewsdesk.com\/index.php\/vibativ-receives-marketing-approval-in-china\/embed\/#?secret=W1UsSze2Ir\" width=\"600\" height=\"338\" title=\"&#8220;VIBATIV\u00ae RECEIVES MARKETING APPROVAL IN CHINA&#8221; &#8212; Market Newsdesk\" data-secret=\"W1UsSze2Ir\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/www.marketnewsdesk.com\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","description":"PR Newswire Vibativ\u00ae is a life-saving antibiotic for pneumonia and serious skin infections Approval in China paves the way for launch in world&#8217;s second-largest market NASHVILLE, Tenn. and SHANGHAI, Feb. 18, 2025 \/PRNewswire\/ &#8212; Specialty pharmaceutical companies Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) and SciClone Pharmaceuticals (Holdings) Limited (&#8220;SciClone Pharmaceuticals&#8221; or &#8220;SciClone&#8221;) today announced the NMPA (National Medical Products Administration) approval of Cumberland&#8217;s Vibativ\u00ae (telavancin) injection in China. The announcement follows an agreement between the companies providing\u00a0SciClone the exclusive rights to register, promote and distribute the product\u00a0to patients in that country. The NMPA is the Chinese pharmaceutical regulatory authority there, equivalent to the United States&#8217; Food and Drug Administration (FDA). Vibativ is a potent, FDA-approved injectable anti-infective that serves as a &hellip; Continue reading \"\"","thumbnail_url":"https:\/\/mma.prnewswire.com\/media\/84325\/cumberland_pharmaceuticals_logo.jpg"}